59 results
425
EX-10.1
NTBL
Notable Labs Ltd
2 Oct 23
Business combination disclosure
5:31pm
States.
(iii)
US $1,500,000 for the first commercial sale of the Covered Product in the European Union.
(iv)
US $750,000 for the first commercial sale
8-K
EX-10.1
NTBL
Notable Labs Ltd
2 Oct 23
Other Events
5:30pm
States.
(iii)
US $1,500,000 for the first commercial sale of the Covered Product in the European Union.
(iv)
US $750,000 for the first commercial sale
424B3
NTBL
Notable Labs Ltd
2 Oct 23
Prospectus supplement
5:29pm
commercial sale of the Covered Product in the European Union.
(iv)
US $750,000 for the first commercial sale of the Covered Product in Japan.
Buyer
424B3
4jf jcpyi
5 Sep 23
Prospectus supplement
6:02pm
S-4/A
i0o p6ajb8hpm
30 Jun 23
Registration of securities issued in business combination transactions (amended)
4:38pm
S-4
EX-10.9
da849
11 May 23
Registration of securities issued in business combination transactions
9:09am
S-4
kr8h2e3
11 May 23
Registration of securities issued in business combination transactions
9:09am
6-K
EX-99.3
iwd8bck06ym1b1qy4
17 May 22
VBL Therapeutics Reports First Quarter 2022 Financial Results
7:00am
6-K
EX-1.1
kxc07cj72ghhymxdsx
11 Feb 22
Current report (foreign)
5:29pm
424B5
48nmi2hpky485weej
11 Feb 22
Prospectus supplement for primary offering
5:28pm
6-K
EX-99.3
laymlik
15 Nov 21
VBL Therapeutics Reports Third Quarter 2021 Financial Results
7:00am
6-K
a9yo9i 70jdpdb
16 Aug 21
Current report (foreign)
7:00am
6-K
b588x
11 May 21
Current report (foreign)
7:00am
POS AM
1feklm2kcci7w1
19 Apr 21
Prospectus update (post-effective amendment)
5:17pm